DeepMed Research

SANOFI PASTEUR

🇫🇷France

Country: 🇫🇷France

Ownership: Subsidiary

Established: 1990-01-01

Employees: 10K

Market Cap: -

Website: http://www.sanofipasteur.com

Clinical Trials

Dose-ranging Study of an Investigational Yellow Fever Candidate Vaccine in Adults

Phase 1

Completed

Conditions: Yellow Fever (Healthy Volunteers)

Interventions: Biological: Yellow fever vaccine
Biological: Yellow fever vaccine (produced on serum-free Vero cells), Dosage 1 vYF vaccine
Biological: Yellow fever vaccine (produced on serum-free Vero cells), Dosage 2 vYF vaccine
Biological: Yellow fever vaccine (produced on serum-free Vero cells), Dosage 3 vYF vaccine

First Posted Date: 2019-10-29

Last Posted Date: 2022-04-25

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 73

Registration Number: NCT04142086

Locations: 🇺🇸
Investigational Site Number 8400001, Silver Spring, Maryland, United States

Study to Assess the Safety and Immunogenicity of a Single Dose of a Quadrivalent Meningococcal (MenACYW) Conjugate Vaccine in Older Adults Who Received a Primary Vaccination (3 or More Years Earlier) in Study MET49

Phase 3

Completed

Conditions: Meningococcal Infection (Healthy Volunteers)

Interventions: Biological: Meningococcal Polysaccharide (serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine
Other: Blood sample

First Posted Date: 2019-10-29

Last Posted Date: 2023-12-19

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 471

Registration Number: NCT04142242

Locations: 🇺🇸
Investigational Site Number 8400021, Greensboro, North Carolina, United States
🇺🇸
Investigational Site Number 8400024, Dallas, Texas, United States
🇺🇸
Investigational Site Number 8400038, Clearwater, Florida, United States

and more 31 locations

Study to Evaluate the Effectiveness of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Adults 65 Years of Age and Older

Phase 3

Terminated

Conditions: Influenza (Healthy Volunteers)

Interventions: Biological: Standard-Dose Inactivated Influenza Vaccine Quadrivalent, Northern Hemisphere strains (QIV-SD)
Biological: Quadrivalent Influenza Vaccine (split virion, inactivated) High-Dose (QIV-HD)

First Posted Date: 2019-10-24

Last Posted Date: 2023-06-08

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 33096

Registration Number: NCT04137887

Locations: 🇫🇮
Investigational Site Number 2469999, Tampere, Finland

Study of Purified Vero Rabies Vaccine Compared With Two Reference Rabies Vaccines, Given in a Pre-exposure Regimen to Children and Adults and as Single Booster Dose to a Subset of Adults

Phase 3

Active, not recruiting

Conditions: Rabies (Healthy Volunteers)

Interventions: Biological: Purified vero rabies vaccine - serum free - VRVg-2
Biological: Purified inactivated rabies vaccine - Verorab®
Biological: Purified inactivated rabies vaccine - Imovax® Rabies

First Posted Date: 2019-10-16

Last Posted Date: 2024-02-09

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 1708

Registration Number: NCT04127786

Locations: 🇹🇭
Investigational Site Number :7640001, Bangkok, Thailand
🇹🇭
Investigational Site Number :7640004, Bangkok, Thailand
🇹🇭
Investigational Site Number :7640003, Bangkok, Thailand

and more 1 locations

Surveillance of Suspected Dengue Cases for Access to Care for Subjects Identified as Seronegative or Undetermined Before Receiving CYD Dengue Vaccine in Previous Clinical Studies in Colombia

Active, not recruiting

Conditions: Dengue Fever

First Posted Date: 2019-10-02

Last Posted Date: 2024-01-12

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 918

Registration Number: NCT04113330

Locations: 🇨🇴
Investigational site Colombia, Colombia, Colombia

Collection of Serum Samples From Children and Older Adults Receiving the 2019-2020 Formulations of Fluzone® Quadrivalent and Fluzone® High-Dose Influenza Vaccines, Respectively

Phase 4

Completed

Conditions: Influenza

Interventions: Biological: Fluzone Quadrivalent vaccine, no preservative (0.5-mL), 2019-2020 formulation
Biological: Fluzone High-Dose vaccine, 2019-2020 formulation

First Posted Date: 2019-09-30

Last Posted Date: 2023-09-28

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 90

Registration Number: NCT04109222

Locations: 🇺🇸
Investigational Site Number 8400002, Bardstown, Kentucky, United States
🇺🇸
Investigational Site Number 8400001, Salt Lake City, Utah, United States

Study to Evaluate the Immune Response After a Booster Dose of a Quadrivalent Meningococcal (MenACYW) Conjugate Vaccine When Administered Alone or Concomitantly With a Licensed Meningococcal Serogroup B Vaccine, in Participants Who Received Primary Quadrivalent Meningococcal Conjugate Vaccine (MCV4)

Phase 3

Completed

Conditions: Meningococcal Immunisation (Healthy Volunteers)

Interventions: Biological: Meningococcal polysaccharide (serogroups A, C, Y, and W) tetanus toxoid Conjugate vaccine MenACYW Conjugate vaccine
Biological: Meningococcal Group B vaccine (Trumenba®)
Biological: Meningococcal group B vaccine (Bexsero®)

First Posted Date: 2019-09-10

Last Posted Date: 2023-09-26

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 570

Registration Number: NCT04084769

Locations: 🇺🇸
Investigational Site Number 8400002, Lincoln, Nebraska, United States
🇺🇸
Investigational Site Number 8400004, Lincoln, Nebraska, United States
🇺🇸
Investigational Site Number 8400012, Birmingham, Alabama, United States

and more 27 locations

Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Europeans Adults 60 Years of Age and Older

Phase 3

Completed

Conditions: Healthy Volunteers
Influenza Immunization

Interventions: Biological: Standard-Dose influenza virus surface antigens (haemagglutinin and neuraminidase), Inactivated, Influenza Vaccine Quadrivalent, 2019-2020 Northern Hemisphere Strains (QIV-SD)
Biological: High-Dose Influenza Vaccine (split virion, inactivated), Quadrivalent (QIV-HD) 2019-2020 Northern Hemisphere formulation

First Posted Date: 2019-07-18

Last Posted Date: 2023-10-03

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 1539

Registration Number: NCT04024228

Locations: 🇧🇪
Investigational Site Number 0560002, Wilrijk, Belgium
🇩🇪
Investigational Site Number 2760003, Berlin, Germany
🇫🇷
Investigational Site Number 2500004, Paris, France

and more 14 locations

Observational Study to Evaluate the Safety of CYD Tetravalent Dengue Vaccine (CYD-TDV) in Pregnant Women and Their Offsprings Inadvertently Exposed During Pregnancy

Completed

Conditions: Dengue Virus Infection

Interventions: Drug: CYD-TDV Dengue Vaccine

First Posted Date: 2019-07-17

Last Posted Date: 2024-01-10

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 104

Registration Number: NCT04023708

Locations: 🇧🇷
Universidade Federal do Paraná Site Number : 1, Curitiba, Paraná, Brazil

Study of Purified Vero Rabies Vaccine Compared With Two Reference Rabies Vaccines in a Simulated Post-Exposure Regimen in Adults

Phase 3

Completed

Conditions: Rabies (Healthy Volunteers)

Interventions: Biological: VRVg-2
Biological: Purified Inactivated Rabies Vaccine
Biological: Human Diploid Cell Vaccine (HDCV)
Biological: Rabies immune globulin (human)

First Posted Date: 2019-05-29

Last Posted Date: 2022-07-19

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 640

Registration Number: NCT03965962

Locations: 🇫🇷
Investigational Site Number 2500001, Rennes Cedex, France
🇫🇷
Investigational Site Number 2500002, Gieres, France

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy